Pediatric phase I trial of LMB-2 [anti-tac-fv-PE38-conjugate] for refractory CD25-positive leukemias and lymphomas.
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Anti-Tac Fv PE38 conjugate (Primary)
- Indications Leukaemia; Lymphoma
- Focus Adverse reactions; Pharmacokinetics
- 30 Apr 2015 Biomarkers information updated
- 20 Oct 2008 'National Cancer Institute - Center for Cancer Research-Medical Oncology' added as study sponsor as reported by ClinicalTrials.gov.
- 01 Jan 2008 New trial record.